Z Radical Contains Nitrogen Patents (Class 514/551)
-
Publication number: 20100324137Abstract: A surface disinfecting composition includes a combination of lauric arginate ethyl ester in combination with EDTA, octenyl succinic acid, octanoic acid, glycolic acid, lactic acid, or combinations thereof. The aqueous solution can be used to disinfect a wide variety of surfaces including food processing and storage equipment, vegetables and fruits, as well as animal carcasses such as poultry.Type: ApplicationFiled: June 17, 2010Publication date: December 23, 2010Applicant: DIVERSEY, INC.Inventor: Michael F. Coughlin
-
Publication number: 20100323990Abstract: The present invention provides the use of prodrugs of pelorol and homopelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions.Type: ApplicationFiled: June 21, 2007Publication date: December 23, 2010Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Raymond Andersen, Matthew Nodwell, Alice Mui
-
Publication number: 20100316749Abstract: The application of L-arginine and its derivatives to the skin causes beneficial effects of wound healing, increasing erectile function and increased growth of hair when applied in sufficient quantity to the skin. A hostile biophysical agent may be combined with the L-arginine to increase its absorption into the skin. The desired concentrations of the hostile biophysical agent is increased when concentration of L-arginine is less than 20% of the concentration of the substance applied to maximize its effect.Type: ApplicationFiled: October 29, 2009Publication date: December 16, 2010Applicant: Strategic Science & Technologies, LLC.Inventor: Eric T. Fossel
-
Patent number: 7850008Abstract: The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R22N—CH2COCH2-CH2CO—OR1 (wherein R1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms; and R2 represents a hydrogen atom or a group R1, and both R2 groups may be the identical or different), and their use in diagnosis and photochemotherapy of disorders or abnormalities of external or internal surfaces of the body, and products and kits for performing the invention.Type: GrantFiled: May 7, 2009Date of Patent: December 14, 2010Assignee: Photocure ASAInventors: Karl E. Gierskcky, Johan Moan, Qian Peng, Harald Steen, Trond Warloe, Alf Bjørseth
-
Publication number: 20100310543Abstract: Described are novel means in the treatment of cerebral neurological conditions such as ischemic insult of the brain. Furthermore, a kit for a non-radioactive protein serine/threonine phosphatase activity assay is provided, which is capable of detecting and distinguishing the activity of PP1, PP2A, and calcineurin (PP2B).Type: ApplicationFiled: July 7, 2008Publication date: December 9, 2010Applicant: UNIVERSITY OF ZURICHInventors: Melissa Farinelli, Isabelle Mansuy, Frabice Heitz
-
Publication number: 20100311791Abstract: The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.Type: ApplicationFiled: December 28, 2007Publication date: December 9, 2010Inventors: Ramin Najafi, Rakesh K. Jain, Timothy P. Shiau, Eddy Low, Satheesh K. Nair
-
Publication number: 20100305165Abstract: Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.Type: ApplicationFiled: May 27, 2010Publication date: December 2, 2010Inventor: Rajesh Manchanda
-
Publication number: 20100297104Abstract: The present invention is in relation to a dendritic molecule having symmetrically sited branches having four or more generations of dendrimers wherein the branch points are tertiary amines linked together with oxygen atom of ether and the heteroatoms are separated by a substituted or non-substituted linear three methylene linker. In addition the invention also provides a process to prepare such dendritic macromolecules.Type: ApplicationFiled: August 14, 2007Publication date: November 25, 2010Applicant: INDIAN INSTITUTE OF SCIENCEInventors: Jayaraman Narayanaswamy, Jayamurugan Govindasamy
-
Publication number: 20100292327Abstract: Use of glycine betaine as therapeutically active ingredient for the preparation of a medicament and/or a nutritional product and/or a dietary supplement for treating human resistant to a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, who suffers from a disease requiring the administration of a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, or who is at risk of suffering of said disease, whereby the medicament comprises an effective amount of glycine betaine for decreasing by at least 10%, advantageously at least 20% the resistance of said patient to said compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereofType: ApplicationFiled: May 19, 2010Publication date: November 18, 2010Inventor: Jallal Messadek
-
Patent number: 7834056Abstract: A composition for hyperuricemia disease or a related disorder, use thereof and method of using thereof are provided.Type: GrantFiled: July 18, 2007Date of Patent: November 16, 2010Inventor: Shuhua Gu
-
Publication number: 20100273725Abstract: The present invention relates to photosensitizer compounds for use in cosmetic and therapeutic applications of photodynamic therapy. The compounds of the present invention are designed for topical application and are characterized by a low permeability to the stratum corneum (the outer skin layer of an individual) and/or a low allergenic potential. Surprisingly, such compounds have beneficial properties in the treatment of certain diseases and lack the undesired damages to healthy skin entailed by prior art compounds. ALA (5-aminolevulinic acid)-esters of body-owned, natural compound such as aminoacids, steroids, carbohydrades, alcohols are preferred, examples of photosensitizers of the present invention. The compounds of the present invention are used in the treatment of skin diseases such as psoriasis, sebaceous glands related conditions including acne, seborrhoic dermatitis, rosacea, skin cancer and precancer, as well as in cosmetic hair removal.Type: ApplicationFiled: December 12, 2008Publication date: October 28, 2010Inventors: Thomas Glanzmann, Jérôme Barge, Georges Wagnieres
-
Publication number: 20100273875Abstract: A composition for external application to skin, containing a compound represented by formula (I) or a salt thereof, and/or a quaternary ammonium salt represented by formula (II): wherein R1 is a substituted or unsubstituted, linear or branched chain alkyl group having 2 to 25 carbon atoms; X is —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO— or —O—; Y is a substituted or unsubstituted alkylene group having 1 to 4 carbon atoms; R2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R3 is an alkyl group having 1 to 4 carbon atoms; R2 and R3 are the same as or different from each other; R4, R5 and R6, which may the same as or different from each other, each are an alkyl group having 1 to 4 carbon atoms; and A? is a counter ion.Type: ApplicationFiled: November 5, 2008Publication date: October 28, 2010Applicant: KAO CORPORATIONInventors: Yasuto Suzuki, Kazue Tsukahara
-
Publication number: 20100260750Abstract: Novel serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation.Type: ApplicationFiled: June 21, 2007Publication date: October 14, 2010Applicant: Ramot At Tel Aviv University LtdInventors: Moshe Rehavi, David Gurwitz
-
Patent number: 7807716Abstract: There is provided novel amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one amino acid ester compound comprising at least one nitric oxide releasing group, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. Also provided are compositions for increasing nitric oxide physiological levels in a subject, methods for increasing nitric oxide physiological levels in a subject, methods for improving a subject's muscle strength, athletic performances and/or lean body mass gain and or performance in a subject.Type: GrantFiled: September 23, 2009Date of Patent: October 5, 2010Assignee: Oral Delivery Technology Ltd.Inventor: Michael Farber
-
Patent number: 7799762Abstract: The present invention is directed in particular to dipeptide-like compounds derived from functionally substituted amino acids, having fatty acid chains bound thereto through amidification of the amine functional groups of said dipeptide-like compounds, one end portion of which bears an accessory functional side chain spacer, with the other end portion being an acid group either in neutral or charged state. Compounds of the present invention have immunomodulating properties like adjuvants, In addition, compounds of the invention can be grafted on a given antigen in order to modulate or tune the immune response or can be equally grafted on a pharmaceutical carrier to enhance the therapeutic effect or targeting thereof. Accordingly, compounds of the invention find use in human and veterinary medicine both as immunogens and diagnostic tools.Type: GrantFiled: December 21, 2000Date of Patent: September 21, 2010Assignee: OM PharmaInventors: Jacques Bauer, Olivier Richard Martin, Sylvain Rodriguez
-
Publication number: 20100227791Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.Type: ApplicationFiled: January 7, 2010Publication date: September 9, 2010Inventors: Gianfranco Peluso, Menotti Calvani
-
Publication number: 20100215707Abstract: Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, compositions for topical delivery of the antibacterial agent and for preventing and/or inhibiting the occurrence or spread of bacterial infection, as well as the growth of odor-causing bacteria, to name a few.Type: ApplicationFiled: February 24, 2010Publication date: August 26, 2010Inventors: Thomas McDonald, Steven Tracy, Annika Weber
-
Publication number: 20100215594Abstract: The invention relates to compounds of the formula I where the substituents AA1, AA2, o and R have a meaning indicated in claim 1, and to the salts and solvates and mixtures thereof, to a process for the preparation thereof, preparations and the use thereof.Type: ApplicationFiled: July 17, 2008Publication date: August 26, 2010Applicant: MERCK PATENT GMBHInventors: Sylvia Huber, Teresa Mujica-Fernaud
-
Patent number: 7772217Abstract: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.Type: GrantFiled: April 14, 2008Date of Patent: August 10, 2010Assignee: N.V. NutriciaInventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
-
Publication number: 20100190688Abstract: Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided.Type: ApplicationFiled: July 12, 2005Publication date: July 29, 2010Inventors: Bin Chao, Thomas L. Deckwerth, Paul S. Furth, Steven D. Linton, Alfred P. Spada, Brett R. Ullman, Michael I. Weinhouse
-
Publication number: 20100173826Abstract: The invention relates to methods of inducing smooth muscle relaxation, for example, a method of inducing relaxation of a vascular or a non-vascular muscle or a method of inducing relaxation of the microvasculature, in a subject in need thereof by promoting the accumulation of protoporphyrin IX in the smooth muscle.Type: ApplicationFiled: March 21, 2007Publication date: July 8, 2010Applicant: NEW YORK MEDICAL COLLEGEInventor: Michael Wolin
-
Publication number: 20100173993Abstract: A controlled release biocidal salt of a first component comprises a cation of a N?—(C1-C22)alkanoyl di-basic amino acid alkyl(C1-C22)ester cationic biocidal molecule and a second component comprising an anion of a monomeric anionic molecule having insignificant biocidal activity. The salt is characterized such that when the salt is exposed to an aqueous medium, the salt partially dissolves thereby releasing biocidal ions in an amount sufficient to exceed the MIC or MBC of a target bacteria being controlled, and further characterized as leaving a residual reservoir of undissolved salt capable of releasing more biocidal ions as the salt is consumed or otherwise removed from the environment encompassing the target bacteria. The preferred cationic biocidal molecule comprises N?-lauroyl-L-arginine ethyl ester (“LAE”).Type: ApplicationFiled: February 4, 2010Publication date: July 8, 2010Inventors: Anthony J. Sawyer, Richard F. Stockel
-
Patent number: 7749503Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.Type: GrantFiled: June 15, 2007Date of Patent: July 6, 2010Assignee: Dynamis Therapeutics, Inc.Inventors: Annette Tobia, Francis Kappler
-
Publication number: 20100158857Abstract: The present invention relates to the treatment and prevention of the toxic effects associated with increased nitric oxide synthase activity in endothelial cells. In particular, the present invention relates to compounds and methods of treatment that inhibit the nitric oxide synthases present in endothelial cells and methods for treating diseases using such compounds and methods.Type: ApplicationFiled: May 23, 2007Publication date: June 24, 2010Inventors: Wolfram Samlowski, Muralidhar Kondapaneni, John McGregor
-
Publication number: 20100144691Abstract: Methods are provided for treating a subject for a fertility condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated to increase the sympathetic activity/parasympathetic activity ratio in a manner that is effective to treat the subject for the condition. Embodiments of the subject invention include modulating a subject's autonomic nervous system using electrical energy and/or one or more pharmacological agents. The subject methods find use in the treatment of a variety of different fertility conditions. Also provided are kits for use in practicing the subject methods.Type: ApplicationFiled: January 22, 2010Publication date: June 10, 2010Inventors: ANTHONY JOONKYOO YUN, Patrick Yuarn-Bor Lee
-
Publication number: 20100144671Abstract: Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.Type: ApplicationFiled: March 3, 2006Publication date: June 10, 2010Applicant: Women and Infants Hospital of RI, Inc.Inventors: Narasimha Swamy, Hema Malini K. Sundaresha
-
Patent number: 7728036Abstract: The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.Type: GrantFiled: November 21, 2005Date of Patent: June 1, 2010Assignees: Erimos Pharmaceuticals, LLC, Johns Hopkins UniversityInventors: Ru Chih C. Huang, Richard Park, Chih-Chuan Chang, Yu-Chuan Liang, David Mold, Elaine Lin, Jonathan Heller, Neil Frazer
-
Publication number: 20100120727Abstract: In one aspect, the present invention provides a composition of a covalent conjugate of an eflornithine analog with an anti-inflammatory drug. In another aspect, the present invention provides a composition of an eflornithine prodrug. In another aspect, the present invention provides a composition of an eflornithine or its derivatives aspirin salt. In another aspect, the present invention provides methods for treating or preventing cancer using the conjugates or salts of eflornithine analogs or eflornithine prodrugs.Type: ApplicationFiled: November 12, 2009Publication date: May 13, 2010Applicant: Kyphia Pharmaceuticals, Inc.Inventor: Feng Xu
-
Publication number: 20100099729Abstract: The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolismsdysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.Type: ApplicationFiled: January 30, 2008Publication date: April 22, 2010Applicant: NICOX S.A.Inventors: Nicoletta Almirante, Stefano Biondi, Ennio Ongini, Laura Storoni, Alessia Nicotra
-
Publication number: 20100093710Abstract: A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed.Type: ApplicationFiled: December 19, 2007Publication date: April 15, 2010Inventors: Philippe Perovitch, Marc Maury
-
Publication number: 20100092420Abstract: Preservative systems on the basis of cationic surfactants are known i n the art, a typical example of such cationic surfactants is the ethyl ester of the lauramide of arginine monohydrochloride (LAE) (2). Besides the chloride form the corresponding bromide and sulphate salts are known. It was found that other salts of the cationic surfactants display excellent properties, such as the salts of lactic acid, glutamic acid and acetic acid. It was further found that the combination of the cationic surfactants with at least one salt of an organic or inorganic acid displayed an excellent preservative action. A further preservative system with favourable properties was the combination of the cationic surfactants with at least one ester compound, amide or enzyme inhibitor. Also the combination of the cationic surfactant with a further cationic molecule such as ethyl arginate, glucosamine or chitosan led to an effective preservative system.Type: ApplicationFiled: August 1, 2005Publication date: April 15, 2010Applicant: LABORATORIOS MIRET, S.A.Inventors: Jordi Miret Carceller, Sergi Figueras Roca, Roger Segret Pons
-
Publication number: 20100093858Abstract: Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.Type: ApplicationFiled: December 18, 2009Publication date: April 15, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Aleardo Koverech, Nicola Pescosolido
-
Publication number: 20100093671Abstract: The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.Type: ApplicationFiled: December 11, 2009Publication date: April 15, 2010Inventors: Richard A. EARL, Maiko EZAWA, Xinqin FANG, David S. GARVEY, Ricky D. GASTON, Subhash P. KHANAPURE, L. Gordon LETTS, Chia-En LIN, Ramani R. RANATUNGE, Stewart K. RICHARDSON, Joseph D. SCHROEDER, Cheri A. STEVENSON, Shiow-Jyi WEY
-
Publication number: 20100087527Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.Type: ApplicationFiled: September 30, 2009Publication date: April 8, 2010Applicant: Codman & Shurtleff, Inc.Inventor: Thomas M. DiMauro
-
Patent number: 7687055Abstract: The method of hardening, fortifying, restructuring, repairing, increasing volume or stabilizing keratinic fibers, especially human hair, includes providing a keratinic fiber treatment composition containing from 0.05 to 1.0 percent by weight of creatine, a salt of creatine, creatinine and/or a salt of creatinine, bringing the keratinic fiber treatment composition into contact with the keratinic fibers and allowing the keratinic fiber treatment composition to remain in contact with the keratinic fibers for a certain time interval.Type: GrantFiled: March 14, 2002Date of Patent: March 30, 2010Assignee: Wella AGInventors: Rudolf Bimczok, Thomas Kripp, Beate Grasser, Christian Springob
-
Publication number: 20100056628Abstract: Green and naturally derived biocides such as N?—(C1-C22) alkanoyl di basic amino acid alkyl (C1 to C22) ester salt cationic molecules can be combined with an anionic molecule not generally considered as having significant biocidal activity to provide antimicrobial, antibacterial, and/or antifungal properties with multifunctional benefits including preservative or self-preserving activity.Type: ApplicationFiled: October 19, 2009Publication date: March 4, 2010Inventors: Richard F. Stockel, Anthony Joseph Sawyer
-
Publication number: 20100056588Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.Type: ApplicationFiled: February 14, 2007Publication date: March 4, 2010Inventors: James Elliot Bradner, Ralph Mazitschek
-
Publication number: 20100034795Abstract: Use of L-carnitine and/or one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of a dietary supplement or medicament for the treatment of corneal diseases is disclosed.Type: ApplicationFiled: June 30, 2006Publication date: February 11, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE IUNITE S.P.A.Inventors: Franco Gaetani, Janos Feher
-
Publication number: 20100028325Abstract: Use of cationic surfactants, derived from the condensation of fatty acids and esterified dibasic amino acids, of the formula (1): occasionally leads to a bitter taste, when the compound is present in a large concentration. The bitter taste can be masked by combination with a second component selected from the list consisting of sucralose, neohespiridin (NHDC), ?-cyclodextrin, mono ammonium glycyrrhizinate (MAG), banana, mentholyptus, sodium dodecyl sulphate (SDS), anetol, menthol, thaumatin, adenosine monophosphate (AMP), aloten, arginine, sodium acetate, arilic acids (ferulic acid, caffeic acid), sclareolide, maltol, anane, phosphatidic acid, eucalyptol, lactisole, lysozyme, lactoglobulin, timol, borneol, acetol, phosphothreonine, phosphotyrosine, phosphoserine, Masking flavour 501521T, Masking flavour 501522, saccharine, aspartame, MK22 N&A FL for masking #25682, MM24 Prosweet N&A FL Enhancer, neodiosmin, xylitol, stevia and Natural and Functional Flavour (NAF®).Type: ApplicationFiled: February 7, 2007Publication date: February 4, 2010Applicant: LABORATORIOS MIRET, S.A.Inventors: Xavier Rocabayera Bonvila, Sergi Figueras Roca, Roger Segret Pons, Eva Piera Eroles
-
Publication number: 20100009933Abstract: The invention relates to the cosmetic use, as a skin moisturizer, of a compound of formula (I): with (i) R1 and R2 represent a hydrogen atom or a C1-C6-alkyl group, or (ii) R1 and R2 can form, together with the nitrogen atom which bears them, a saturated heterocycle with 5 to 7 ring members; R5 representing a hydrogen atom or a (C1-C3) alkyl group; R6 representing a hydrogen atom or a (C1-C4) alkyl group; R3 represents a hydrogen atom or a (C1-C6) alkyl-group, or —OR3 represents a phosphate group; it being possible for the two groups R3 to form, together, an isopropylidene group; R4 represents a hydrogen atom or —OR4 represents a-phosphate group; and the salts, solvates and isomers thereof. The invention also relates to a cosmetic composition comprising a compound (I) and the corresponding new compounds.Type: ApplicationFiled: May 3, 2007Publication date: January 14, 2010Applicant: L'OREALInventor: Xavier Marat
-
Publication number: 20100010084Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: July 15, 2009Publication date: January 14, 2010Inventor: Chongxi Yu
-
Publication number: 20090325963Abstract: A method of delivering a curcuminoid to a patient, which includes iontophoretically delivering a charged curcuminoid across the skin of an Alzheimer's Disease patient.Type: ApplicationFiled: June 27, 2008Publication date: December 31, 2009Inventors: Sean Lilienfeld, Thomas M. Di Mauro
-
Publication number: 20090326031Abstract: Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the protection against the growth of the microorganisms. The cationic surfactants of this type are also effective against virus infections. Addition of LAE to cultures of Herpes virus type 1 Vaccinia virus and bovine parainfluenzae 3 virus leads to nearly complete reduction of the virus organisms in these cultures, such effects being observed after 5 and 60 minutes.Type: ApplicationFiled: August 3, 2006Publication date: December 31, 2009Applicant: NOVACYTInventors: Xavier Rocabayera Bonvila, Sergi Figueras Roca, Roger Segret Pons
-
Publication number: 20090312419Abstract: Disclosed are creatine ?-alaninate, compositions and formulations containing same, and methods of use therefor.Type: ApplicationFiled: August 21, 2009Publication date: December 17, 2009Inventor: Bruce W. Kneller
-
Patent number: 7632836Abstract: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.Type: GrantFiled: November 28, 2007Date of Patent: December 15, 2009Assignee: CeNeRx Biopharma, Inc.Inventor: Michael Rafferty
-
Publication number: 20090304584Abstract: Conjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a psychotropic drug.Type: ApplicationFiled: July 17, 2007Publication date: December 10, 2009Applicants: Ramot At Tel Aviv University Ltd., Bar-IIan University, BioLine RX Ltd.Inventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman, Ran Lifshitz, IIan Winkler
-
Publication number: 20090298782Abstract: Disclosed are compounds containing single amino acids, peptides, or derivatives thereof which are selectively delivered to the mitochondria of a cell. Compounds of the invention exhibit antioxidant activity thereby reducing reactive oxygen species in cells. These compounds are useful for inhibiting oxidative stress-induced cell injury or death both in vivo and ex vivo. In addition, methods for the synthesis of these compounds are disclosed.Type: ApplicationFiled: December 18, 2006Publication date: December 3, 2009Applicant: UNIVERSITY OF ROCHESTERInventors: Shey-Shing Sheu, Marion W. Anders, Lin Xu, Virendra K. Sharma, Dhananjaya Nauduri
-
Patent number: 7622117Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.Type: GrantFiled: July 18, 2002Date of Patent: November 24, 2009Assignee: Dynamis Therapeutics, Inc.Inventors: Annette Tobia, Francis Kappler
-
Publication number: 20090286878Abstract: Anti-microbial compositions are provided which comprise as an antimicrobial agent at least one compound derived from a select polyol containing at least 3 hydroxy groups wherein one or more, and often two or more, of the hydroxyls are derivitized to form certain ether, ester, carbonate or carbamate groups which groups may bear additional functionality. Novel antimicrobial compounds of this class are also provided. The compositions are effective against a variety of pathogens including fungi, Gram positive bacteria and Gram negative bacteria and are expected to have low human toxicity. Applications for the polyglycerol anti-microbial agents and compositions include those involving human and plant contact, such as cosmetics, hair care products, textiles and plant protections, as well as in applications with much less human contact, such as plastics, coatings, wood, paper and other materials of construction.Type: ApplicationFiled: May 14, 2009Publication date: November 19, 2009Inventors: Stewart Todd Elder, Fadi Khawam, Xinyu Huang, Werner Holzl
-
Publication number: 20090275630Abstract: Composition containing, in a physiologically acceptable medium, at least one imidopercarboxylic acid compound and at least one N-acylated amino acid ester of formula (A) as described herein.Type: ApplicationFiled: March 20, 2009Publication date: November 5, 2009Applicant: L'OREALInventors: Roxane Provost, Geoffroy Remaut, Cecile Kermorvan, Celine Moussay